Phase I study of novel SYK inhibitor TAK‐659 (mivavotinib) in combination with R‐CHOP for front‐line treatment of high‐risk diffuse large B‐cell lymphoma

Autor: Reem Karmali, Frederique St‐Pierre, Shuo Ma, Kelly D. Foster, Jason Kaplan, Xinlei Mi, Barbara Pro, Jane N. Winter, Leo I. Gordon

Publikováno v: eJHaem, Vol 4, Iss 1, Pp 108-114 (2023)

Abstract Background: TAK‐659, a novel oral SYK inhibitor, has demonstrated efficacy in heavily pretreated diffuse large B‐cell lymphoma (DLBCL). We report results of a phase I single‐institution escalation study of front‐line treatment with R

Externí odkaz: https://doaj.org/article/4ddec0d795ad48768f1172140048cc49

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma : updated data with mivavotinib (TAK-659/CB-659)

Autor: Gordon, Leo I, Karmali, Reem, Kaplan, Jason B, Popat, Rakesh, Burris, Howard A, Ferrari, Silvia, Madan, Sumit, Patel, Manish R, Gritti, Giuseppe, El-Sharkawi, Dima, Chau, F Ian, Radford, John, de Oteyza, Jaime Pérez, Zinzani, Pier Luigi, Iyer, Swaminathan P, Townsend, William, Miao, Harry, Proscurshim, Igor, Wang, Shining, Katyayan, Shilpi, Yuan, Ying, Zhu, Jiaxi, Stumpo, Kate, Shou, Yaping, Carpio, Cecilia, Bosch, Francesc

Publikováno v: Gordon, L I, Karmali, R, Kaplan, J B, Popat, R, Burris, H A, Ferrari, S, Madan, S, Patel, M R, Gritti, G, El-Sharkawi, D, Chau, F I, Radford, J, de Oteyza, J P, Zinzani, P L, Iyer, S P, Townsend, W, Miao, H, Proscurshim, I, Wang, S, Katyayan, S, Yuan, Y, Zhu, J, Stumpo, K, Shou, Y, Carpio, C & Bosch, F 2023, ' Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma : updated data with mivavotinib (TAK-659/CB-659) ', Oncotarget, vol. 14, pp. 57-70 . https://doi.org/10.18632/oncotarget.28352
Scientia

Non-Hodgkin’s lymphoma; SYK inhibitor; Relapsed/refractory Linfoma no Hodgkin; Inhibidor de SYK; Recidivante/refractario Limfoma no Hodgkin; Inhibidor de SYK; Recaiguda/refractària We report an updated analysis from a phase I study of the spleen t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::611458e735d4ba1168636765aa9dcd81
https://ddd.uab.cat/record/271599

Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma

Autor: Osman Cen, Karuppiah Kannan, Jessica Huck Sappal, Jie Yu, Mengkun Zhang, Muzaffer Arikan, Ali Ucur, Duran Ustek, Yeter Cen, Leo Gordon, Richard Longnecker

Publikováno v: mSphere, Vol 3, Iss 4 (2018)

ABSTRACT Epstein-Barr virus (EBV) is associated with several B and epithelial cell cancers. EBV-encoded latent membrane protein 2A (LMP2A) contributes to cellular transformation by mimicking B cell receptor signaling. LMP2A/MYC double transgenic mice

Externí odkaz: https://doaj.org/article/48f85aa45d2b44e28e440291bf2c7228

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma

Autor: Mengkun Zhang, Ali Ucur, Yeter Cen, Karuppiah Kannan, Jie Yu, Duran Ustek, Leo I. Gordon, Richard Longnecker, Osman Cen, Muzaffer Arikan, Jessica Huck Sappal

Publikováno v: mSphere, Vol 3, Iss 4 (2018)
mSphere
mSphere, Vol 3, Iss 4, p e00378-18 (2018)

The novel SYK and FLT3 inhibitor TAK-659 prevents the enlargement of spleen and tumor development in a mouse model of EBV-associated lymphoma by counteracting the activation of cellular kinase SYK through the viral LMP2A gene by inducing cell death i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f766f9f015ffebf131bea37cdbb4e19
https://journals.asm.org/doi/10.1128/mSphereDirect.00378-18